Get started

Trading

BITCOIN Will Fall! Sell! Please, check our technical outlook for BITCOIN. Time Frame: 1D Current Trend: Bearish Sentiment: Overbought (based on 7-period RSI) Forecast: Bearish The price is testing a key resistance 108,838.74. Taking into consideration the current market trend & overbought RSI, chances will be high to see a bearish movement to the downside at least to 101,845.14 level. P.S The term oversold refers to a condition where an asset has traded lower in price and has the potential for a price bounce. Overbought refers to market scenarios where the instrument is traded considerably higher than its fair value. Overvaluation is caused by market sentiments when there is positive news. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis. Like and subscribe and comment my ideas if you enjoy them!
TRADENATION:BTCUSDShort
by SignalProvider
1
USD/CHF BULLS WILL DOMINATE THE MARKET|LONG Hello, Friends! Bullish trend on USD/CHF, defined by the green colour of the last week candle combined with the fact the pair is oversold based on the BB lower band proximity, makes me expect a bullish rebound from the support line below and a retest of the local target above at 0.828. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis. ✅LIKE AND COMMENT MY IDEAS✅
Long
by EliteTradingSignals
1
USD/JPY SENDS CLEAR BEARISH SIGNALS|SHORT Hello, Friends! USD-JPY uptrend evident from the last 1W green candle makes short trades more risky, but the current set-up targeting 142.829 area still presents a good opportunity for us to sell the pair because the resistance line is nearby and the BB upper band is close which indicates the overbought state of the USD/JPY pair. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis. ✅LIKE AND COMMENT MY IDEAS✅
Short
by EliteTradingSignals
1
MarketBreakdown | USDJPY, USDCAD, BITCOIN, SILVER Here are the updates & outlook for multiple instruments in my watch list. 1️⃣ #USDJPY daily time frame 🇺🇸🇯🇵 The market nicely respected a rising trend line and bounced from that, forming a high momentum bullish candle. I think that the pair will continue rising and reach 145.8 level soon. 2️⃣ #USDCAD daily time frame 🇺🇸🇨🇦 The price is currently approaching an important confluence zone based on a falling trend line and a horizontal support. I will expect a pullback from that. 3️⃣ #BITCOIN #BTCUSD daily time frame The price successfully violated a resistance line of a bullish flag pattern and closed above that. It is a critical bullish signal. I believe that the price will test a current high then and will violate that with a high probability. 4️⃣ #SILVER #XAGUSD daily time frame 🪙 The market broke a resistance line of a bullish flag. Uptrend is going to continue, and the price is going to reach 37,14 level soon. Do you agree with my market breakdown? ❤️Please, support my work with like, thank you!❤️ I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
Long
by VasilyTrader
9
EUR-JPY Will Keep Growing! Buy! Hello,Traders! EUR-JPY is trading in an Uptrend and the pair broke The key horizontal level Of 169.814 and the breakout Is confirmed so after a potential Retest of the support cluster Of the rising and horizontal Support lines below we will Be expecting a bullish continuation Buy! Comment and subscribe to help us grow! Check out other forecasts below too! Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
Long
by TopTradingSignals
1
TSLA bearish: Musk vs Trump! Subsidy Spotlight & Sentiment RisksIf you haven`t bought TSLA before the recent breakout: Now you need to know that Tesla (TSLA) is sitting around $315, but the vibe is getting shakier. Elon Musk’s feud with Donald Trump — complete with jokes about “putting the DOGE on him” if deported — might feel like another meme moment, but it spotlights Tesla’s huge dependency on federal and state support. Estimates show Tesla could face up to $48 billion in lost government contracts and incentives over the next decade if the political tide turns. With Trump’s base calling out “green subsidies” as wasteful, Tesla’s funding pipeline could get squeezed — just as competition ramps up and margins get tighter. Key Bearish Points 1) Political Risk Is Real Musk’s public fight with Trump is a double-edged sword: he risks losing goodwill on both sides of the aisle. If the next administration decides to gut EV credits, Tesla could take a huge hit — far more than its rivals who rely less on U.S. incentives. 2) Subsidy Dependence Tesla’s success is partly built on a foundation of tax credits, carbon credits, and favorable policies. $48B in potential lost value is nothing to shrug off — especially when competitors like BYD are gaining ground. 3) Bearish Technical Setup TSLA’s chart is rolling over inside a bearish channel. It recently failed to hold the $330 level and now sits around $315. A clean breakdown below $300 could open the door to your target zone at $262 — a major support area from earlier this year. Catalysts: Any new comments from Trump’s camp about EV subsidies Weak delivery/margin numbers from Tesla Broader tech/equity pullback Musk’s crypto distractions no longer propping up sentiment Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
TRADENATION:TSLAShort
by TopgOptions
VKTX: Unusual Options Flow & a Breakthrough Weight-Loss DrugIf you haven`t bought CKTX before the recent rally: Now you need to know that Viking Therapeutics (VKTX) is a speculative biotech stock in the GLP-1/GIP agonist space, aiming to challenge market leaders like Eli Lilly and Novo Nordisk. Recently, I noticed unusual options flow — specifically, Jan 16, 2026 $60 strike calls Key Bullish Points 1) Riding the Obesity Drug Boom VK2735 is Viking’s dual agonist candidate showing promising early weight-loss efficacy, with potential overlap benefits in NASH (liver disease). The obesity treatment space is expected to exceed $100B by 2030—huge upside if their trials continue positively. 2) Options Flow Tells a Story Those Jan 2026 $60 calls caught my attention precisely because the stock currently trades in the mid-$60s. These aren’t cheap lottery plays—they’re strategically timed wrt trial readouts, partnerships, or acquisition interest. Essentially, someone anticipates meaningful upside in the near future. 3) Descending Wedge — Chart Looks Bullish VKTX peaked near $100, then pulled back into a well-defined descending wedge. If it breaks out above $70–$72 with volume, that could kick off a classic reversal trade. Smart Money Options Flow — Near-Term Bet: Recently, I spotted unusual open interest in $60 strike calls expiring Jan 16, 2026 — that’s only about 7 months away. This means someone is positioning for a big upside move relatively soon, likely betting on positive Phase 2b/3 data, a partnership deal, or even buyout chatter within the next few quarters. Short-dated, out-of-the-money call flow like this often hints at near-term news — not just a long-dated hedge.
NASDAQ:VKTXLong
by TopgOptions
KWEB: China’s Internet Sector - AI Catch-Up and Cheap ValuationsChina’s internet and tech stocks have been hammered for years — regulatory crackdowns, slowing growth fears, and geopolitical tension have crushed sentiment. But as investors know, the best opportunities often hide in what everyone hates. Enter KWEB, the KraneShares CSI China Internet ETF. It’s a diversified, liquid way to play a bounce in major names like Alibaba, Tencent, JD .com, Baidu, Meituan and PDD. Here’s why I think the risk/reward looks compelling now — especially if you believe in AI closing the gap. Key Bullish Points: 1) Valuations at Rock-Bottom Many big China internet stocks are still trading at single-digit P/E ratios, even as their cash flows recover. Compared to U.S. big tech trading at 30–50x, this is a huge valuation gap. Regulatory fears seem largely priced in — Beijing wants growth, not stagnation, and some policies are easing. 2) China’s AI Push — Just “Months Behind” Jansen Whang recently argued that China’s generative AI development is only “months behind” the U.S. Players like Baidu, Alibaba Cloud, Tencent, and SenseTime are all racing to launch new LLMs and integrated AI tools. If you believe the gap closes, Chinese platforms could see a major earnings rebound as they roll out AI upgrades across search, cloud, e-commerce and social media. 3) Sentiment So Bad, It’s Good When the headlines scream “China is uninvestable,” that’s often when big mean reversion trades set up. Even a small policy pivot, stimulus plan, or positive AI news cycle can spark a sharp rally. KWEB is one of the cleanest ways to express this view because it holds a diversified basket — you don’t have to pick a single winner.
AMEX:KWEBLong
by TopgOptions
Why IonQ (IONQ) Could Be the NVDA of Quantum ComputingIf you haven`t bought IONQ before the rally: Now you need to know that IonQ isn’t just another speculative quantum stock — The company is building a robust ecosystem around its best‑in‑class trapped‑ion architecture and targeting fault‑tolerant, networked quantum systems. With record bookings, major acquisitions, and a strong balance sheet, IonQ could emerge as the NVIDIA equivalent for quantum infrastructure. Key Bullish Arguments 1) Superior Quantum Tech – Trapped‑Ion Advantage IonQ’s trapped-ion processors boast 99.9% two-qubit fidelity, demonstrating higher accuracy and scalability than superconducting alternatives These systems also operate at room temperature, meaning simpler deployment and lower costs 2) Ecosystem Strategy & Acquisitions The $1.08B acquisition of Oxford Ionics (expected close in 2025) expands IonQ’s qubit control tech, pushing toward planned 80,000 logical‑qubit systems by decade’s end Combined with ID Quantique and Lightsynq, IonQ is building a full-stack quantum and networking offering 3) Strong Revenue Growth & Cash Runway Revenue soared from $22M in 2023 to $43.1M in 2024, with bookings of $95.6M . Q1 2025 saw $7.6M revenue and EPS –$0.14, beating expectations; cash reserves near $697M provide years of runway 4) Real Commercial Deployments IonQ sold its Forte Enterprise quantum system to EPB ($22M deal) for hybrid compute and networking, marking real-world commercial applications 5) AI & Quantum Synergy Involvement in NVIDIA’s Quantum Day and hybrid quantum‑classical AI demos (e.g., blood pump simulation with Ansys, ~12 % faster) indicates strategic synergy and positions IonQ as a critical piece in the future AI stack Recent Catalysts: Texas Quantum Initiative passes – positions IonQ at forefront of U.S. state-backed innovation Oxford Ionics acquisition pending – major expansion in qubit scale & tech Barron’s analyst buys – industry analysts see long-term potential; IonQ among top quantum picks Broader quantum optimism – McKinsey & Morgan Stanley forecasts highlight synergy between quantum and AI, benefiting IonQ
NYSE:IONQLong
by TopgOptions
CRSP Could Crack the Holy Grails of Medicine: Cancer & AlzheimerWhen Tesla (TSLA) started, few believed a scrappy EV startup could transform the entire auto industry and ignite a green energy revolution. But it did. Today, CRISPR Therapeutics (NASDAQ: CRSP) is quietly doing something similar for medicine — and if you squint, its upside might be even bigger than Tesla’s. Gene Editing: The Next Industrial Revolution — For Your Cells CRISPR/Cas9 gene editing is like biological software. It gives scientists the power to cut, delete, or rewrite genes — the source code of life — with surgical precision. CRISPR Therapeutics was co-founded by Dr. Emmanuelle Charpentier, a Nobel Prize winner who helped pioneer this breakthrough. The company’s lead therapy, exa-cel — just FDA approved in the U.S. — is the first-ever CRISPR-based gene-editing treatment to hit the market. First up: curing devastating blood disorders like sickle cell disease and beta-thalassemia — a $10 billion+ opportunity. But that’s only the start. Aging: The Ultimate Disease What if we treated aging itself as a disease? Many scientists now argue that growing old is the result of accumulated genetic errors, cellular damage, and mutations — processes that can be slowed or even reversed. Gene editing holds the promise to repair DNA damage, reprogram cells, and treat the root causes of age-related decline. If successful, it could extend healthy human lifespan by decades. Think about that: Tesla made cars last longer and burn cleaner. CRSP could make you last longer and live healthier. The Two Holy Grails: Cancer and Alzheimer’s Beyond blood disorders, CRISPR Therapeutics is working on a pipeline targeting solid tumors, diabetes, and more. But the real game-changers are cancer and Alzheimer’s disease — the twin mountains every biotech company dreams of conquering. With gene editing, we could one day rewrite the genetic mutations that fuel cancer growth or remove the faulty proteins that clog the brain in Alzheimer’s. These are trillion-dollar problems — and the company that cracks them will reshape human history. Built for Scale — Like Tesla CRSP isn’t going at it alone. Partnerships with Vertex, Bayer, and ViaCyte help spread risk and amplify impact. With over $2 billion in cash, it has the runway to execute — just as Tesla used capital to build factories and charging networks at scale. The market still underestimates that this is a platform company — not a single-drug biotech. If Tesla went from cars to batteries, solar, and AI, CRSP could go from blood disorders to rewriting the code for life itself. Bottom Line Aging. Cancer. Alzheimer’s. These are the holy grails of medicine. If you missed Tesla at $20 a share, CRISPR Therapeutics could be your second chance — the TSLA of Gene Editing. Because the greatest disruption of all is not electric cars. It’s the chance that, one day, growing old will be optional.
NASDAQ:CRSPLong
by TopgOptions
7
INJ Long Swing Setup – Structural Recovery with SMA ReclaimINJ has retraced to a key support zone and is showing early signs of recovery, reclaiming its 20-day SMA. With structural strength returning, the $11.00–$11.60 range offers a solid swing entry—contingent on BTC holding key levels. 📌 Trade Setup: • Entry Zone: $11.00 – $11.60 • Take Profit Targets: o 🥇 $14.00 – $16.00 o 🥈 $19.80 – $23.00 • Stop Loss: Daily close below $9.50 (Exit early if BTC breaks major support)
Long
by Richtv_official
2
GOLD Massive Long! BUY! My dear subscribers, This is my opinion on the GOLD next move: The instrument tests an important psychological level 3326.7 Bias - Bullish Technical Indicators: Supper Trend gives a precise Bullish signal, while Pivot Point HL predicts price changes and potential reversals in the market. Target - 3337.9 My Stop Loss - 3320.0 About Used Indicators: On the subsequent day, trading above the pivot point is thought to indicate ongoing bullish sentiment, while trading below the pivot point indicates bearish sentiment. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis. ——————————— WISH YOU ALL LUCK
TRADENATION:XAUUSDLong
by AnabelSignals
1